Diabetic Foot, Ulcer Foot, Wound Heal
Conditions
Keywords
Diabetic foot ucer, Wound closure matrix, Wound healing, Chronic wound
Brief summary
Supra SDRM® is FDA-cleared as a dressing for treating partial and full-thickness wounds. It is a dermal substitute that provides a barrier and an ECM-like structure to help accelerate wound healing. SUPRA SDRM® has 510k approval for partial and full-thickness wounds and has shown promising results in preliminary animal studies. The purpose of this clinical evaluation is to collect and compare outcomes data from patients with UT 1A diabetic foot ulcers treated with a commercially available dermal substitute, Supra SDRM®, as compared to an advanced standard of care (Fibracol Plus). Patient outcomes, including time to heal, healing by 12 weeks, direct costs, and infection rate, will be compared at the end of the study.
Detailed description
Chronic wounds are those that fail to proceed through the normal phases of wound healing. They pose a high risk for infection and risk complications resulting in amputation. A plethora of wound treatment modalities are commercially available to help improve patient outcomes. However, even when combined with a good standard of care practices and wound dressings, they may not be sufficient to promote timely wound closure. Cellular and/or tissue- based products (CTPs) may provide a healing advantage over traditional dressings. CTPs are derived from human (allograft), animal (xenograft), or synthetic materials or a combination thereof. CTPs can help encourage tissue repair or regeneration by providing scaffolds and the cells necessary to stimulate wound healing. Synthetic products may provide advantages over human or other animal sourced products because they are natural, non-biologic, avoid complications due to risk of disease transmission, and possess less immunologic potential. The fully synthetic skin substitute evaluated in this study is SUPRA SDRM® Synthetic Biodegradable Matrix Wound Dressing (Polymedics Innovations Inc.; Woodstock,GA). The device is a novel synthetic, guided wound closure matrix, built as a bimodal foam membrane structure for the management of chronic wounds. It combines the benefits of a microporous structure that builds a protective barrier allowing the wound to heal and additional large pores which were created to enable ingrowth of blood vessels. This microenvironment initially provides a seal against contamination and modulates inflammation in wound bed. Subsequently, it supports cellular processes required for tissue repair and wound healing. In this parallel randomized clinical trial, patients with diabetic foot ulcers grade UT 1A will receive either standard of care plus SUPRA SDRM or a collagen dressing (Fibracol Plus) weekly after wound debridement. Primary outcomes will be time to achieve wound healing, and the proportion of patients achieving healing by 12 weeks. Secondary outcomes will include the direct costs of treatment and the proportion of patients who developed infections during the trial.
Interventions
PROCEDUREWound debridement
The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.
DEVICEWound closure matrix application
After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.
Sponsors
McGill University
Polymedics Innovations Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males and females aged 18 or older. * Subject is willing to sign an informed consent and participate in all procedures and follow-up evaluations. * Study ulcer is diabetic in origin, located on foot or below the malleolus (UT Grade 1A). * Study ulcer size is a minimum of 2 cm2 and a maximum of 25 cm2. * Study ulcer has been present for a minimum of 4 weeks before enrollment and less than 1 year old. * Study ulcer has been offloaded for at least 14 days before randomization. * Subject does not exhibit clinical signs or symptoms of infection. * Subject has adequate control of diabetes demonstrated by Hemoglobin A1c \< 12% within 90 days of screening. * Subject has adequate circulation to the affected extremity.
Exclusion criteria
* Study ulcer has \> 40% wound healing during the 14 days screening period. * Subject has a known history of poor compliance with medical treatments. * Subject is presently participating in another clinical trial. * Subject has a known or suspected local or systemic malignancy. * Subject has been diagnosed with autoimmune connective tissues diseases. * Subject has received graft material or topical growth factors on the study ulcer within the previous 30 days. * Subject has received application of topical steroids on the study ulcer surface within the previous 30 days. * Subject is pregnant or breast feeding. * Subject is on dialysis. * Subject is taking medications that are considered immune system modulators or cytotoxic chemotherapies. * Subject cannot be on systemic antibiotics prior to randomization, however, during the treatment phase infection management may include systemic antibiotics if in conjunction with debridement. * Subject has a known allergy to ingredients/components of Supra SDRM®. * Subject has osteomyelitis, and/or bony prominences present in the wound. * Subject has ulcer probing to bone and tendon. (UT Grade II or III A-D). * Subject is unable to comply with planned study procedures and treatments.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to heal | Up to 30 weeks | Number of weeks required to achieve 100% epithelization of the wound |
| Healing by 12 weeks | 12 weeks | Proportion of patients achieving 100% epithelization on or before week 12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Direct costs | Up to 30 weeks | Direct costs of treatment |
| Infection rate | Up to 30 weeks | Proportion of patients developing an infection in the wound bed |
Countries
United States
Outcome results
None listed